Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice
Frédérique Dol-Gleizes(Sanofi (France)), Françoise Bono(OSE Immunotherapeutics (France)), Anne-Marie Marés(Inserm), Virgile Visentin(Inserm), Bart Staels(Inserm), Réjane Paumelle(Inserm), Paul Schaeffer(Universidad La Salle), Andries J. Gilde(Inserm), Perrine Desitter(Inserm), Nathalie Hennuyer(Inserm)
Cited by 124
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
|Journal of Hepatology|2014|1.5k
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
|Journal of Biological Chemistry|1999|1.1k